- Home
- TNGX vs SNN Comparison
TNGX vs SNN Comparison
Compare TNGX & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- SNN
- Stock Information
- Founded
- TNGX 2014
- SNN 1856
- Country
- TNGX United States
- SNN United Kingdom
- Employees
- TNGX N/A
- SNN N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- SNN Industrial Specialties
- Sector
- TNGX Health Care
- SNN Health Care
- Exchange
- TNGX Nasdaq
- SNN Nasdaq
- Market Cap
- TNGX 735.0M
- SNN 12.4B
- IPO Year
- TNGX N/A
- SNN 1999
- Fundamental
- Price
- TNGX $6.64
- SNN $29.44
- Analyst Decision
- TNGX Strong Buy
- SNN Strong Buy
- Analyst Count
- TNGX 8
- SNN 1
- Target Price
- TNGX $15.14
- SNN N/A
- AVG Volume (30 Days)
- TNGX 885.7K
- SNN 674.7K
- Earning Date
- TNGX 11-06-2024
- SNN 08-01-2024
- Dividend Yield
- TNGX N/A
- SNN 2.55%
- EPS Growth
- TNGX N/A
- SNN 39.77
- EPS
- TNGX N/A
- SNN 0.35
- Revenue
- TNGX $42,509,000.00
- SNN $5,642,000,000.00
- Revenue This Year
- TNGX $18.15
- SNN $6.92
- Revenue Next Year
- TNGX N/A
- SNN $5.43
- P/E Ratio
- TNGX N/A
- SNN $41.81
- Revenue Growth
- TNGX 26.16
- SNN 5.48
- 52 Week Low
- TNGX $6.33
- SNN $21.53
- 52 Week High
- TNGX $13.01
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- TNGX 37.15
- SNN 46.87
- Support Level
- TNGX $6.83
- SNN $28.26
- Resistance Level
- TNGX $7.47
- SNN $29.64
- Average True Range (ATR)
- TNGX 0.37
- SNN 0.36
- MACD
- TNGX 0.11
- SNN 0.05
- Stochastic Oscillator
- TNGX 27.31
- SNN 58.65
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.